Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor?

Drug Discov Today. 2023 Feb;28(2):103467. doi: 10.1016/j.drudis.2022.103467. Epub 2022 Dec 14.

Abstract

Perinatal depression is the most common psychiatric complication of pregnancy, with its detrimental effects on maternal and infant health widely underrated. There is a pressing need for specific molecular biomarkers, with pregnancy-related decline in brain-derived neurotrophic factor (BDNF) in the blood and downregulation of TrkB receptor in the brain reported in clinical and preclinical studies. In this review, we explore the emerging role of BDNF in reproductive biology and discuss evidence suggesting its deficiency as a risk factor for perinatal depression. With the increasing evidence for restoration of serum BDNF levels by antidepressant therapy, the strengthening association of perinatal depression with deficiency of BDNF supports its potential as a surrogate endpoint for preclinical and clinical studies.

Keywords: TrkB receptor; estradiol; fluid biomarker; neuroplasticity; perinatal affective disorder; postpartum depression; pregnancy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antidepressive Agents / pharmacology
  • Antidepressive Agents / therapeutic use
  • Biomarkers
  • Brain / metabolism
  • Brain-Derived Neurotrophic Factor / metabolism
  • Depression* / drug therapy
  • Depressive Disorder* / drug therapy
  • Female
  • Humans
  • Pregnancy

Substances

  • Brain-Derived Neurotrophic Factor
  • Antidepressive Agents
  • Biomarkers